Echo Pharmaceuticals Announces Phase 2 Results for Namisol(R), Its' Pipeline Product for Oral Administration of DELTA9

Echo Pharmaceuticals Announces Phase 2 Results for Namisol(R), Its' Pipeline 
Product for Oral Administration of DELTA9-Tetrahydrocannabinol and Appoints 
The Sage Group 
AMSTERDAM, CAMBRIDGE, England and CLINTON, New Jersey, July 11, 2013 /CNW/ - 
Echo Pharmaceuticals ("Echo") announces that Namisol(R) has completed 
successfully a Phase II trial with 24 patients suffering from spasticity and 
pain due to multiple sclerosis (MS). The trial has been conducted by the 
Centre for Human Drug Research (CHDR) in the VU University Medical Center 
Amsterdam and it was led by Dr. G.J. Groeneveld, Research Director Neurology & 
Pain, CHDR. The clinical trial was a double blind, placebo-controlled study of 
Namisol(R) to determine safety, tolerability and efficacy in MS patients. The 
outcome of this trial showed efficacy and consistent results on both 
spasticity and pain. 
(Logo: ) 
Simultaneously, The Sage Group has been appointed by Echo Pharmaceuticals to 
assist the company in its search for a strategic partner for commercialisation 
of its lead Namisol(R) program. 
Dr. Vanesa Fernandez, CEO of Echo Pharmaceuticals, said "We are very pleased 
that The Sage Group has been selected by our Company to assist in the 
commercialisation phase of Namisol(R). The successful Phase 2 trial in MS 
patients is a major milestone for Echo and we believe there will be strong 
global interest in working with us to take the product to market. The Sage 
Group are very experienced in developing such partnerships and will add a 
valuable business development activity to our drug development capability." 
Dr. Bill Mason and Wayne Pambianchi of The Sage Group based in Europe and the 
USA said "We are delighted to be selected as managers for this exciting 
program and we look forward to working with Echo and key interested parties in 
the pharma industry to develop strong partnerships for global 
commercialisation of Namisol(R)." 
About Namisol(R) Namisol(R) is the world's first oral tablet that contains 
pure (greater than or equal to98,0%), natural DELTA9-tetrahydrocannabinol (THC 
or dronabinol) in fixed dosages with high, predictable bioavailability (due to 
Echo's innovative drug delivery technology AlitraTM) and a long, stable shelf 
life at room temperature. Namisol(R)'s current clinical program includes, in 
addition to the MS indication, a number of phase II clinical trials for the 
indications behavioral disturbances in patients with Alzheimer's Disease 
e ], and Chronic Pain 
[ ]. 
About Echo Pharmaceuticals B.V. ("Echo") Echo Pharmaceuticals is a privately 
owned, specialized pharmaceutical company based in The Netherlands, founded in 
2006. Their mission is to develop effective medicines, with a focus on 
cannabinoid-based compounds, and drug delivery technologies that contribute to 
better the quality of life for a wide range of patients. In 2009, Echo 
established their headquarters and clinical research center in Nijmegen, which 
is situated in an area of the Netherlands well-known for its ideal environment 
for businesses in life sciences and health. 
Over the years, Echo has developed outstanding proprietary knowledge and 
extensive expertise in the field of isolation, formulation and clinical 
development that have led to successful drug- and delivery technology 
development programs. Echo Pharmaceuticals has a cGMP certified production and 
pharmaceutical development center in Weesp, The Netherlands 
About The Sage Group, Inc. The Sage Group Inc. is a leader in the provision of 
strategic and transactional advice to health care companies in the 
pharmaceutical, diagnostics, medical device, biotechnology and life science 
fields. Sage currently maintains offices in USA, Europe, Israel, Australia and 
Japan. Since its founding in 1994, The Sage Group has served more than 200 
clients in the US, Europe and Asia, and completed numerous transactions 
including divestitures, alliances, acquisitions and financings with values 
ranging from $5 million to $500 million. 
The Sage Group is an organization of experienced and successful executives who 
are committed to the service of the very vital and dynamic health care 
industry and its investors. 
Contact Details 
Sage Europe: Dr. W. T. Mason Director, Sage Healthcare Tel: +44-(0)1638-508779 
Sage USA: Wayne Pambianchi Director, Sage Healthcare Tel: +1-908-2306170 
Echo Pharmaceuticals Netherlands: Dr. Vanesa Fernandez CEO, Echo 
Pharma Tel: 
SOURCE: Echo Pharmaceuticals 
To view this news release in HTML formatting, please use the following URL: 
CO: Echo Pharmaceuticals
ST: New Jersey 
-0- Jul/11/2013 16:05 GMT
Press spacebar to pause and continue. Press esc to stop.